PLUS THERAPEUTICS, INC. — Director's Dealing 2016

Jun 16, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTORI THERAPEUTICS, INC. (CYTX)
CIK: 0001095981
Period of Report: 2016-06-15

Reporting Person: LYONS GARY A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-06-15	Common Stock	X	1900	—	Acquired	4358	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-06-15	Subscription Rights (Right to Buy)	$2.55	X	1900	Disposed	2016-06-10	See Footnote (1900)	Indirect
2016-06-15	Warrants (Right to Buy)	$3.06	X	950	Acquired	2018-12-14	Common Stock (950)	Indirect

Footnotes

F1: The Reporting Person maintains indirect ownership of these securities in his capacity as sole trustee and beneficiary of The Gary A. Lyons Revocable Living Trust U/A, DTD 6/8/2102 (the "Trust"), including 2,458 shares previously reported as directly held that were transferred by the Reporting Person to the Trust.

F2: The common stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company) to all holders of the Company's common stock. The subscription rights entitled each recipient thereof to purchase units ("Units"). Each Unit consists of one share of the Company's common stock and 0.5 of a warrant, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $2.55.

F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $3.06 from the date of issuance through December 14, 2018.